The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Bakhtiyarova K.Z.

Bashkir State Medical University

Boyko O.V.

Federal Center for Brain Research and Neurotechnology

Dudin V.A.

Center for Cardiology and Neurology»

Zaslavsky L.G.

Pavlov First Saint Petersburg State Medical University

Malkova N.A.

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

Parshina E.V.

Semashko Nizhny Novgorod Regional Clinical Hospital

Poverennova I.Ye.

Seredavin Samara Regional Clinical Hospital

Sivertseva S.A.

Medical and Sanitary unit «Neftyanik»

Totolyan N.A.

Academician I.P. Pavlov First Saint Petersburg State Medical University

Shchur S.G.

Municipal Filatov Clinical Hospital No. 15

Khabirov F.A.

City Clinical Hospital No. 7;
Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education

Goncharova Z.A.

Rostov State Medical University

Zakharova M.N.

Research Center of Neurology

Bolsun D.D.

AO BIOCAD

Zinkina-Orikhan A.V.

AO BIOCAD

Linkova Yu.N.

AO BIOCAD

Chernovskaya T.V.

JSC «BIOCAD»

Porozova A.A.

JSC «BIOCAD»

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

Authors:

Boyko A.N., Bakhtiyarova K.Z., Boyko O.V., Dudin V.A., Zaslavsky L.G., Malkova N.A., Parshina E.V., Poverennova I.Ye., Sivertseva S.A., Totolyan N.A., Shchur S.G., Khabirov F.A., Goncharova Z.A., Zakharova M.N., Bolsun D.D., Zinkina-Orikhan A.V., Linkova Yu.N., Chernovskaya T.V., Porozova A.A.

More about the authors

Views: 1770

Downloaded: 39


To cite this article:

Boyko AN, Bakhtiyarova KZ, Boyko OV, et al. . Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(2):52‑59. (In Russ.)
https://doi.org/10.17116/jnevro202312302152

Recommended articles:
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Questionnaires for arm function asse­ssment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42
Features of primary forms of headache in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73
Neurofilament light chain: a diagnostic pote­ntial for multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.